Forschung

Studiennummer: INTEGRATE IIb
Studientitel: Eine randomisierte, unverbindete klinische Studie der Phase III zur Prüfung von Regorafenib plus Nivolumab gegen die Standard-Chemotherapie bei refraktärem fortgeschrittenem Magen-Ösophagus-Karzinom
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: PHERFLOT
Studientitel: Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma – A phase II trial of the AIO study group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: PRESTO
Studientitel: Organerhalt durch Immuntherapie auf Durvalumab-Basis in Kombination mit Chemotherapie und Bestrahlung als definitive Therapie für Adenokarzinome des Ösophagus im Frühstadium (cT1 und cT2N0) mit Indikation zur Radikaloperation: Eine prospektive, multizentrische Studie der FLOT-AIO Gastric Cancer Group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: Ramiris II/III
Studientitel: Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: ACO/ARO/AIO 18.2
Studientitel: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure:
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Cirulate (AIO-KRK-0217)
Studientitel: Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: Fire-8-Port (AIO-KRK/YMO-0519):  
Studientitel: Prospective, randomized, open, multicenter Phase II trial to investigate the effcacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: Fire-9-Port (AIO-KRK-0418):  
Studientitel: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: MK1808A-008
Studientitel: Eine multizentrische, mehrarmige Phase-II-Studie zur Bewertung von MK-1308A (koformuliertes Quavonlimab (MK-1308)/ Pembrolizumab) im Vergleich zu anderen Behandlungen bei Teilnehmern mit kolorektalem Karzinom im Stadium IV mit hoher Mikrosatelliteninstabilität (MSI-H) oder Mismatch-Reparatur-Defekt (dMMR).
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: CheckMate (CA209-274)
Studientitel: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 274)
Verantwortlicher Arzt: Prof. Dr. Susanne Krege
Status: geöffnet

Studiennummer: Antelope (AIO-TRK-0122)
Studientitel: Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: iTeos A2A-005
Studientitel: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: Dolpin
Studientitel: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Originalarbeiten ab 2021

1. Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzmar A, Köhne CH, ….. Krämer A, Arbeitsgemeinschaft Internistische Onkologie – CUP Group. (2021) Adding Cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the phase II AIO trial PACET-CUP. Brit J Cancer 124:721-7.
2. Ertl S, Heuer H-C, Stahl M. (2021) How an oncologist´s intuition compares to a geriatric assessment. Oncol Res Treat 44:111-18.
3. Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, Stahl M, Reichardt P, Sökler M, Pink D, Probst S, Hinke A, Goetze T, Al-Batran S. (2022) FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 165:48-57.
4. Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner AD, Girschofsky M, Eboulet E, Stahl M, Ruhstaller T. (2022) Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. Eur J Cancer 177:186-93.
5. Stahl M, Ertl S, Engelmeyer P, Heuer H, Christoph D (2023) Impact of geriatric assessment on the tolerability of combination chemotherapy in older patients with advanced cancer: a matched-pair analysis. Cancer Res Treat 46:100-104.
6. Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Riera Knorrenschild J, Illerhaus G, Dechow T, Moehler M, Moulin J, Pink D, Stahl M, Schaaf M, Goetze T, Al-Batran S. (2023) Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer 23:561-9.
7. Porschen R, Fischbach W, Gockel I, Hollerbach S, ……, Stahl M, Vanhoefer U, Ebert M, (2023) S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Z Gastroenterol 61:701-45.
8. Lordick F, Al-Batran S, Arnold D, Borner M, ……, Stahl M, Maschmeyer G (2023) German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer DOI: 10.1007/s10120-023-01424-y.
9. Baretton G, Lordick F, ……., Stahl, P-Thuss-Patience, Tiemann K. (2023) Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J Cancer Res Clin Oncol 149; 16231-38.
10. Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, …. Stahl M, …Michiels S, on behalf of the MANATEC-02 collaborative group. (2023) Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemradiotherapy in esophageal or gastroesophageal junction carcinoma. J Cin Oncol 41:4535-47.
11. Stintzing S, Heinrich K, Tougeron D, Modest D, Schwaner I, Eucker J, …, Müller C, ……., Taieb J, Heinemann V. (2023) FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study PMID. J Clin Oncol. DOI: 10.1200/JCO.22.01420
12. Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. (2021): Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 13:1758835920980558.
13. Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Grünwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC (2021): Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. J Immunother Cancer 9(3):e002262.
14. Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD (2021): Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers (Basel) 13(8):1761.
15. Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm MO, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K (2021): Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers (Basel) 13(11):2594.
16. Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE (2021): A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 13:1758835921996506.
17. Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD (2021): Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Transl Lung Cancer Res 10(7):3030-3042.
18. Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J (2022): A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. Transl Lung Cancer Res. 11(1):75-86.
19. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022): Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J Thorac Oncol. 18:181-193
20. Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD (2023). Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model. Int J Mol Sci. 24(15):12426.

Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, Pérol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 31 (S4), P1242. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska -Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) Ann Oncol. 31 (S4), P1244.

Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Ann Oncol. 31 (S4), MO1896. Kurzvortrag auf der Jahrestagung der European Society of Medical Oncology 2020.

Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (202):  Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol. 31 (S4), P1374. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

Shah R, Klotz LV, Feißt M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, Jürgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N,  Bischoff H, Winter H , Eichhorn M, Thomas M (2020):  NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol. 31 (S4), TiP1912. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.